The Danish pharmaceutical giant Novo Nordisk is rising on the Copenhagen Stock Exchange after presenting a new study of the weight loss drug Amycretin. The stock is surging over 8 percent.
The clinical study shows that people treated with the drug lost 9.7 percent of their weight after 20 weeks. After 36 weeks, the patients had lost 22 percent of their weight.
Amycretin is a pill for weight loss, unlike Novo Nordisk's previous weight loss preparations Wegovy and Ozempic, which are injected into the patient.
According to Novo Nordisk, they are planning for further clinical development of the drug.
